EGFR and small cell lung carcinoma: In addition to genomic retention of EGFR mutations, recent clinical analyses have shown that EGFR-mutant proteins and EGFR-related signaling pathways may remain detectable at the time of SCLC/NEC transformation and in subsequent re-biopsy samples, highlighting a potential disconnect between lineage identity and oncogenic pathway activity [41].